Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Review: 1 At first, I was doubtful, but the results were amazing
Key features: Higher systemic bioavailability Slower clearance , particularly with IM injections Stronger effects on muscles, tendons, ligaments, and nerves May stay in circulation for 68 hours , with extended biological action beyond that Injectable BPC-157 leads to wide systemic distribution and is particularly effective for connective tissue injuries and neurological repair. Sikiric, P
It also helps increase metabolic energy and improve mood regulation
Through promoting collagen synthesis, angiogenesis, and cell migration, BPC-157 supports structural healing in tissues damaged by Lyme-related inflammation
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
US$ 20.86
US$ 24.71
US$ 28.42
